Malaysia secures 150,000 courses of Molnupiravir for Covid-19 treatment
Malaysia has signed an agreement with Merck & Co. to obtain 150,000 courses of the experimental antiviral drug Molnupiravir as part of its transition to managing Covid-19 as an endemic disease.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthMalaysia secures 150,000 courses of Molnupiravir for Covid-19 treatment
Sign in or subscribeBrowse free archive reportsMalaysia has signed an agreement with Merck & Co. to obtain 150,000 courses of the experimental antiviral drug Molnupiravir as part of its transition to managing Covid-19 as an endemic disease.